Intermediate-Dose Cytarabine Matches High-Dose Efficacy with Fewer Side Effects in Postinduction AML Therapy
Highlights
- Intermediate-dose cytarabine (IDAC) demonstrated noninferior overall survival compared to high-dose cytarabine (HDAC) in postinduction AML therapy for patients aged 18–60 years.
- IDAC resulted in reduced hematologic toxicity and fewer adverse events compared to HDAC, without compromising efficacy.
- The benefit of IDAC was consistent across major risk groups and response strata, supporting its generalizability.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.